Tag Archives: panelist

Insights from Genomics Investors Panelists

3 May

By Jessica Yang, Investor Research Analyst, LSN

During RESI on MaRS – as part of Toronto Health Innovation Week – we invited five panelists from renowned investment groups focusing on genomics to share their insights. How do they assess the genomics-related areas of investment?

Moderated by Ihor Boszko, Vice President, Business Development, Ontario Genomics, the Genomics Investor Panelists were:

Here are some takeaway points from the panel discussion:

Tools, platforms, and technologies
Q: What do you see as exciting opportunities on the platforms/tools side of genomics? Is it in the decentralization of sequencing? Other genomics technologies?

  1. The key is to think about what kinds of applications and markets these companies are targeting. When investors look at new sequencing platforms, they are thinking about what differentiates these new technologies from centralized sequencing – what can these platforms do that centralized sequencing cannot? For innovative genomics companies, they must identify their target markets and specific applications they want to address in the decentralized models.
  2. From different angles, all points to the same direction – the guiding principle of making investments in the healthcare arena is looking for unique and differentiated technologies that address unmet needs. The other is costs, anything expanding access while lowering the cost speaks to investor’s interests. For example, platform technologies that make things cheaper, better, or faster, making it practical in clinical settings – this is what the investors are looking for.

Direct-to-consumer in Genomics

Q: What do you think about direct-to-consumer products in Genomics?

  1. More and more direct-to-consumer products come out on the market, and it’s getting easier for everyone to do it. However, genetics and genomics are complicated. In the current healthcare system, most people aren’t trained to order or interpret the results. The challenge is that training and sophistication will lag behind the technology for computers.

Some of these direct-to-consumer tasks are negatively impacting their reputation as it relates to quality. One of the ethics dilemmas around direct-to-consumer products is that people don’t understand the terms and conditions, and some of that is companies selling consumer data,

Meet the Family Office Panelists at RESI Toronto

5 Apr

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

For every RESI event, the LSN Investor Research team aims to recruit a diverse slate of panels with experienced investors of all types and focus areas within life science technology. As one of the more highly sought types of investors for entrepreneurs, Family Offices is a recurring panel at RESI. Mostly backed by private wealth as evergreen funds, family offices often have deep connections in the life science field both professionally and, at times, personally—some family office investors have loved ones battling debilitating diseases. Family offices are highly idiosyncratic with their own motivations and strategies, though despite their differences and founding stories, they continue to play actively within life science investment.

On April 10th at RESI Toronto, we will hear from four family offices that invest in several different life science sectors. Moderated by Catherine Love, Director of Capital Services for MaRS Discovery District, the panelists include:

  • Sherry Grisewood, Chief Investment Office, Foxhill Asset Management
  • David Ramos, CFO, AGP Holdings
  • Chuck Stetson, CEO, Stetson Family Office
  • Oded Levi, President, Epstein Enterprises

Register now for RESI Toronto at the MaRS Discovery District on April 10th to hear from these experienced individuals.

RESI Panel Announcement – Diagnostic Investors

30 Mar

By Lucy Parkinson, Director of Research, LSN

Diagnostics is a challenging landscape for fundraising and commercialization; however, the sector attracts interest and backing from a wide variety of stakeholders. There are many unmet needs in the sector, from finding new disease biomarkers to improving monitoring of progressive diseases.

The range of diagnostic investors attending RESI on MaRS next Tuesday provide testament to this varied landscape, with interest in novel diagnostic technologies coming from major pharma and device companies, diagnostic service providers, venture investors, and government organizations. RESI will bring the diagnostics world together for a panel discussion, moderated by Bob Williams, Vice President, Business Development and Innovation – Bracco Diagnostics, and featuring:

These investors will introduce their own specific angle on the diagnostics sector, and will cover what they look for in an investment opportunity in this sector. Panelists will also provide advice on how to make a new diagnostic catch their attention as an investable product. If you’d like to hear the advice of these experts at RESI, there’s still time to sign up.

RESI San Francisco Asia Pacific Investors Panel

26 Jan

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

During JPM this year, close to 1,000 investment professionals from China gathered in San Francisco, according to unofficial statistics. What hot sectors are they looking for? How can you initiate and maintain a relationship with them? At RESI San Francisco, entrepreneurs and investors filled up the Asia Pacific Investors panel room to learn about the nuts and bolts of cross-border investment.

Moderated by Jimmy Lu, Managing Director, WI Harper Group, the panelists include:

Key takeaway points from the panel:

  • Chinese investors are pushed to look overseas by the following forces: asset price, scarcity of high-quality products, and scarcity of exit in the public market. Many of them are seeking one or more of the following factors from US early stage companies: cutting-edge technologies, large sales potential in their domestic markets, and access to the US market.
  • The Chinese government’s new currency restriction has impacted some transactions and created uncertainty in the future. Dual currency funds (firms that manage domestic RMB and offshore USD funds) are less affected.
  • To engage a Chinese partner, it is key to identify a ‘China hook’ of your product. Large patient population is only one factor. Regulatory process, medical practice, and reimbursement should also be considered.
  • A good partnership can come in different forms: direct investment, licensing, joint venture, M&A, etc. Entrepreneurs should work with experienced investors to form a partnership that is most suitable for their product sector and stage.

RESI San Francisco Panel Announcement: Tech Giants in Healthcare

29 Dec

By Michael Quigley, VP of Market Research, LSN

mike-2

Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.

Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:

  • Iana Dimkova, Senior Associate, Healthcare, GE Ventures
  • Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
  • Rich Wilmot, Head of Corporate Venturing, Philips
  • Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS

In this session, a number of investors at these large firms will discuss their involvement in healthcare innovation ecosystem. What types of technologies they are interested in? How much data do they like to see pre-investment? What problems in the space are they looking to tackle? These questions and more will be answered at RESI on Jan 10th so if you’re looking to partner with a large tech company for your product this is a panel you don’t want to miss.

RESI San Francisco Panel Announcement: Big Pharma

10 Nov

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

As we gear up for the biggest RESI event of the year, during the heavily anticipated JPM week, we’re happy to once again announce the Big Pharma panel. This is typically one of the most popular panels at the RESI conference, and for good reason – large pharmaceutical and biotech companies, through a variety of deal structures, are looking earlier and earlier for assets, but tend to represent a daunting challenge for entrepreneurs seeking to successfully engage and navigate.

Senior-level executives from some of the world’s top pharmaceutical companies will provide some color around their process and strategy, and how entrepreneurs can best prepare to present to and work with organizations like theirs.

Big Pharma panelists will include the following:

  • Monica Viziano, Sr. Director, Business Development, Gilead
  • Barbara Sosnowski, VP External R&D Innovation, Pfizer
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Christian Schubert, Director, Corporate Development & Strategy, Biogen
  • Jeremy Grunstein, Executive Director, Business Development, Amgen

By registering for RESI San Francisco on January 10 (Tuesday of JPM week), you’ll be able to listen to this panel live and gain insight into the dynamics of partnering with a strategic player as well as experience numerous opportunities to expand your network in the life sciences and learn more about the fundraising process in general.

resi-san-francisco-2017

RESI San Francisco Panel Announcement: Corporate VCs & Strategic Investment

3 Nov

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking externally for innovative technologies, and strategic venture investments are a key part of many firms’ strategies for participating in the early stage ecosystem.  Firms may use subsidiary corporate venture funds, or may have an internal unit for making strategic investments in startups that are relevant to their pipeline.

At RESI San Francisco on Tuesday January 10th, the Corporate VC panel will bring together investors from 5 different corporate VCs to cover how they invest on behalf of their parent pharma companies.

The panelists are:

In this panel, corporate VC investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and how they bridge the gap between early stage startups and major pharmaceutical corporations.

If you’d like to be there in person, you can register for RESI now.

resi-san-francisco-2017

%d bloggers like this: